Threat to three DMTs removed after manufacturers cut prices

Manufacturers of three relapsing multiple sclerosis drugs have cut prices to remain available to Britain's National Health Service (NHS). They are all diseases modifying therapies (DMTs). In January, I brought you news that five such drugs were under threat, having been found to be not cost-effective as long-term therapy options. In a draft recommendation from … Continue reading Threat to three DMTs removed after manufacturers cut prices

Significant profits at stake in MS drug patent battle

It is well known that pharmaceutical companies make a great deal of money from their products.  It is also indisputable that they make significant profit from the drugs they sell to treat those of us with chronic illnesses, including multiple sclerosis. There are widespread beliefs that some companies manipulate the system to gain further patent … Continue reading Significant profits at stake in MS drug patent battle